Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer Review uri icon

Overview

MeSH Major

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Estrogens
  • Prostatic Neoplasms

abstract

  • Androgen deprivation therapy (ADT) is the standard of care for metastatic prostate cancer and is increasingly used to treat asymptomatic patients with prostate-specific antigen recurrence after failed primary therapy. Although effective, ADT is associated with multiple adverse effects, many of which are related to the estrogen deficiency that occurs as a result of treatment. These include increased fracture risk, hot flashes, gynecomastia, serum lipid changes and memory loss. By providing clinicians with a greater awareness of the estrogen deficiency induced adverse effects from ADT, they can proactively intervene on the physical and psychological impact these effects have on patients.

publication date

  • December 2, 2009

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1038/pcan.2009.35

PubMed ID

  • 19901933

Additional Document Info

start page

  • 333

end page

  • 8

volume

  • 12

number

  • 4